PRE VS CLGN Stock Comparison

Performance

PRE
10/100

PRE returned -86.81% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

CLGN
10/100

CLGN returned 0.00% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

Technicals

PRE
36/100

PRE receives a 35 of 100 based on 14 indicators. 4 are bullish, 8 are bearish.

CLGN
14/100

CLGN receives a 14 of 100 based on 14 indicators. 1 are bullish, 11 are bearish.

Earnings

PRE
44/100

PRE has missed earnings 2 times in the last 20 quarters.

CLGN
10/100

CLGN has missed earnings 11 times in the last 20 quarters.

Profit

PRE
13/100

Out of the last 10 quarters, PRE has had 2 profitable quarters and has increased their profits year over year on 1 of them.

CLGN
22/100

Out of the last 20 quarters, CLGN has had 4 profitable quarters and has increased their profits year over year on 3 of them.

Volatility

PRE
55/100

PRE has had a higher than average amount of volatility over the last 12 months giving it a score of 54 of 100.

CLGN
52/100

CLGN has had a higher than average amount of volatility over the last 12 months giving it a score of 52 of 100.

All score calculations are broken down here to help you make more informed investing decisions

Prenetics Global Limited Class A Ordinary Share Summary

Nasdaq / PRE

Healthcare

Medical - Diagnostics & Research

Prenetics Global Limited, an investment holding company, operates as a diagnostics and genetic testing company. Its products include CircleDNA, a consumer genetic testing product; and Circle HealthPod, a rapid detection health monitoring system that allows users to take COVID-19 tests at point-of-care or at home utilizing the nucleic acid amplification test. The company's products also comprise ColoClear, a non-invasive FIT-DNA colorectal cancer screening test; Circle SnapShot, an off-the-shelf at-home blood test; Circle Medical, a diagnostic testing product; and Circle One and F1x/Fem. Prenetics Global Limited was founded in 2014 and is headquartered in Quarry Bay, Hong Kong.

CollPlant Biotechnologies Ltd Ordinary Shares Summary

Nasdaq / CLGN

Healthcare

Biotechnology

CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, and Europe. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology. The company's products include BioInks for 3D printing of tissues and organs; dermal filler and soft tissue fillers for treating wrinkles; 3D Bioprinted breast implants for regeneration of breast tissue; injectable implants to promote breast tissue regeneration; 3D bioprinted regenerative soft tissue matrix; VergenixSTR, a soft tissue repair matrix intended for the treatment of tendinopathy; and VergenixFG, an advanced wound care product for the treatment of deep surgical incisions and wounds, including diabetic ulcers, venous and pressure ulcers, burns, bedsores, and other chronic wounds. It has collaboration agreements with 3D Systems Corporation; CellInk, a BICO Group company; Advanced Regenerative Manufacturing Institute; RegenMed Development Organization; Israel's Technion Institute of Technology; AbbVie; and STEMCELL. The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd. in June 2019. CollPlant Biotechnologies Ltd. was founded in 2004 and is headquartered in Rehovot, Israel.

Power up your portfolio